Karsten Kueppenbender, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychotherapeutic Processes | 1 | 2012 | 50 | 0.410 |
Why?
|
| Group Processes | 1 | 2012 | 227 | 0.370 |
Why?
|
| Psychotherapy, Group | 2 | 2012 | 417 | 0.370 |
Why?
|
| Psychoanalytic Therapy | 1 | 2012 | 217 | 0.360 |
Why?
|
| Neostriatum | 2 | 2000 | 236 | 0.310 |
Why?
|
| Spouse Abuse | 1 | 2008 | 182 | 0.260 |
Why?
|
| Child Abuse, Sexual | 1 | 2008 | 400 | 0.240 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2000 | 903 | 0.230 |
Why?
|
| Amphetamine | 1 | 2004 | 222 | 0.210 |
Why?
|
| Ventral Tegmental Area | 1 | 2004 | 135 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 474 | 0.210 |
Why?
|
| Calcium Channels, L-Type | 1 | 2004 | 244 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 478 | 0.210 |
Why?
|
| Life Change Events | 1 | 2008 | 960 | 0.200 |
Why?
|
| Suicide | 1 | 2012 | 1606 | 0.190 |
Why?
|
| Adaptation, Psychological | 2 | 2012 | 2663 | 0.180 |
Why?
|
| Alcoholism | 2 | 2008 | 1980 | 0.160 |
Why?
|
| Receptors, Glutamate | 1 | 1999 | 229 | 0.160 |
Why?
|
| Child Abuse | 1 | 2008 | 1091 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2004 | 1168 | 0.130 |
Why?
|
| Alternative Splicing | 1 | 1999 | 1105 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 2188 | 0.100 |
Why?
|
| Neural Pathways | 2 | 2000 | 3117 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2004 | 12800 | 0.100 |
Why?
|
| Neurons | 2 | 2000 | 9514 | 0.090 |
Why?
|
| Grief | 1 | 2012 | 256 | 0.090 |
Why?
|
| Social Support | 2 | 2012 | 2193 | 0.080 |
Why?
|
| Choline O-Acetyltransferase | 2 | 2000 | 156 | 0.080 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 1903 | 0.080 |
Why?
|
| Reactive Attachment Disorder | 1 | 2008 | 42 | 0.070 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2008 | 300 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2012 | 724 | 0.070 |
Why?
|
| Alcoholics Anonymous | 1 | 2006 | 32 | 0.070 |
Why?
|
| Alcohol Deterrents | 1 | 2006 | 49 | 0.070 |
Why?
|
| Clinical Clerkship | 1 | 2012 | 569 | 0.070 |
Why?
|
| Family Therapy | 1 | 2008 | 214 | 0.070 |
Why?
|
| Naltrexone | 1 | 2008 | 319 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 8542 | 0.060 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 135 | 0.060 |
Why?
|
| Low Back Pain | 1 | 2012 | 990 | 0.050 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2012 | 1085 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 591 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 327 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2008 | 886 | 0.050 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 358 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2004 | 1647 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 687 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2004 | 8128 | 0.050 |
Why?
|
| Psychiatry | 1 | 2012 | 1716 | 0.040 |
Why?
|
| Tachykinins | 1 | 2000 | 77 | 0.040 |
Why?
|
| Enkephalins | 1 | 2000 | 139 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 4818 | 0.040 |
Why?
|
| Glutamate Decarboxylase | 1 | 2000 | 239 | 0.040 |
Why?
|
| Borderline Personality Disorder | 1 | 2006 | 767 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 5536 | 0.040 |
Why?
|
| Psychotherapy | 1 | 2008 | 1654 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 11095 | 0.040 |
Why?
|
| Physician-Patient Relations | 2 | 2012 | 3269 | 0.040 |
Why?
|
| Parvalbumins | 1 | 1999 | 256 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 2748 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2006 | 2697 | 0.030 |
Why?
|
| Rats | 2 | 2004 | 23760 | 0.030 |
Why?
|
| Comorbidity | 2 | 2008 | 10590 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2000 | 1134 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 3837 | 0.030 |
Why?
|
| Recurrence | 1 | 2008 | 8509 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1715 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2004 | 8317 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 10760 | 0.020 |
Why?
|
| Pain Clinics | 1 | 2012 | 50 | 0.020 |
Why?
|
| Male | 6 | 2018 | 364719 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2006 | 5130 | 0.020 |
Why?
|
| Female | 5 | 2018 | 397192 | 0.020 |
Why?
|
| Humans | 8 | 2018 | 768166 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 223646 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2012 | 1260 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 8741 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 40218 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2006 | 726 | 0.010 |
Why?
|
| Middle Aged | 4 | 2018 | 223492 | 0.010 |
Why?
|
| Animals | 2 | 2004 | 169246 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 3436 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2006 | 1988 | 0.010 |
Why?
|
| Child | 1 | 2008 | 80917 | 0.010 |
Why?
|
| Curriculum | 1 | 2012 | 3782 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2012 | 4858 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2006 | 6029 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 65371 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 14783 | 0.010 |
Why?
|
| Prevalence | 1 | 2006 | 15869 | 0.000 |
Why?
|
| Aged | 1 | 2000 | 171504 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 39348 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2006 | 54926 | 0.000 |
Why?
|
| Risk Factors | 1 | 2006 | 74944 | 0.000 |
Why?
|
| Adolescent | 1 | 2006 | 89169 | 0.000 |
Why?
|